+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 55Years
All Genders
ID06636786

Evaluating Sublingual Cyclobenzaprine HCl TNX-102 SL to Reduce Acute Stress Reaction and Post-Traumatic Stress After Motor Vehicle Collision

Led by University of North Carolina, Chapel Hill · Updated on 2026-10-22

180

Participants Needed

9

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of TNX-102 SL, a sublingual form of cyclobenzaprine HCl, to reduce symptoms of acute stress reaction ASR and behavioral changes in patients who visit the emergency department after a motor vehicle collision. This study focuses on whether starting TNX-102 SL soon after the collision can reduce ASR and acute stress disorder symptoms, enhance neurocognitive function, and prevent or lessen posttraumatic stress symptoms over time. The trial is a double-blind, placebo-controlled randomized clinical trial involving 180 participants. Participants will receive either TNX-102 SL or a matching placebo sublingual tablet starting in the emergency department. They will take an initial half dose in the ED, with dosing on the first night adjusted based on the time until bedtime, followed by a full dose at bedtime each night for two weeks. Each participant will receive 28 or 29 tablets to complete the treatment. The placebo tablets are designed to look and weigh the same as the active drug but do not contain cyclobenzaprine. Throughout the study, participants will undergo regular assessments of psychological and physical symptoms, neurocognitive function, and any adverse events from the time of enrollment and during the following weeks. The main outcome measured is the change in acute stress disorder scores at 1 and 3 weeks after the collision. Additional outcomes include tests of cognitive reaction time, attention, pain symptoms, depressive symptoms, somatic symptoms, and posttraumatic stress symptoms measured at multiple time points up to 12 weeks after the collision. The study is sponsored by the University of North Carolina, Chapel Hill, with a planned completion in late 2026.

CONDITIONS

Brief Title

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

Research Team

R

Romina Soudavari

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here